New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 30, 2012
18:34 EDTPFEPfizer completes sale of nutrition business, $10B share buyback now in effect
Pfizer announced that it has completed the sale of its nutrition business to Nestle for $11.85B in cash, following the conclusion of the required regulatory process in most markets. In certain countries where completion will be delayed due to ongoing regulatory review, Pfizer will continue to operate the business on an interim basis. "The completion of the sale of the Nutrition business to Nestle demonstrates our commitment to maximizing the value of our businesses and prudently managing capital. We remain focused on enhancing shareholder value, and our new $10B share repurchase program is now effective upon the completion of the sale and will be utilized over time," said CFO Frank D'Amelio.
News For PFE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
February 2, 2016
12:03 EDTPFEOn The Fly: Top stock stories at midday
Wall Street began the session in negative territory and the averages have remained there throughout the day as oil once again weighs on stocks. The price of oil has slid another 4%, giving the commodity a roughly 10% loss over the past two trading sessions. The market's late day rally yesterday gave hope for a decoupling between equities and oil prices, but that appears to be a one day reprieve as the stocks are back in lock-step with crude prices. ECONOMIC EVENTS: In the U.S., the economic calendar was quiet. In Europe, statistics agency Eurostat reported that unemployment across the eurozone decreased by 49,000 to a total of 16.75M in December dropping the unemployment rate to its lowest since September 2011 at 10.4%. In central bank news, the Reserve Bank of Australia and Reserve Bank of India both held their benchmark interest rates steady, as expected. COMPANY NEWS: Class A shares of Alphabet (GOOGL) advanced 5% in the wake of its report of better than expected quarterly earnings and revenue, pushing Google's parent company to overtake Apple (AAPL) as the world's most valuable publicly-traded company in the process... Exxon Mobil (XOM) reported better than expected revenue and profits in the fourth quarter, but its shares slid 2.5% amid the renewed weakness in oil prices. Shares of fellow oil major BP (BP) plunged 8% in New York trading after reporting a steep quarterly loss, largely due to $2.6B in charges related to impairments of Upstream assets as well as restructuring... Pfizer (PFE) reported better than expected fourth quarter results, but forecast 2016 revenue and earnings below analysts' estimates, pushing its shares down fractionally. MAJOR MOVERS: Among the notable gainers was Syngenta (SYT), which rallied 4.5% after Bloomberg reported that ChemChina was close to a deal to buy the company for nearly $43B. Also higher were Mattel (MAT), Michael Kors (KORS), and Fabrinet (FN), which gained 12%, 22%, and 12.5%, respectively, after reporting quarterly earnings. Among the noteworthy losers was Twitter (TWTR), which fell 8% after it was downgraded to Sell at Stifel and following a report claimed that tweets on the service are down 50% from their peak. Also lower were AGCO (AGCO), Harris (HRS), and Pitney Bowes (PBI), which were down 10%, 9.5%, and 11%, respectively, after reporting quarterly earnings. In addition, Ford (F) and General Motors (GM) lost 4% and 3.6%, respectively, after reporting U.S. sales for the month of January. INDEXES: Near midday, the Dow was down 239.86, or 1.46%, to 16,209.32, the Nasdaq was down 64.83, or 1.4%, to 4,555.54, and the S&P 500 was down 27.87, or 1.44%, to 1,911.51.
11:10 EDTPFEPiper says buy Axovant on today's Pfizer-related selloff
Piper Jaffray analyst Charles Duncan calls the pullback in shares of Axovant Sciences (AXON) after Pfizer (PFE) announced the discontinuation of its 5-HT6 antagonist program in Alzheimer's a buying opportunity. Axovant's RVT-101 has "clear differences" to Pfizer's program on potency, clinical trial design and patient enrollment criteria, Duncan tells investors in an intraday research note. The analyst views clinical read-through between the two programs as minimal and does not believe the probability of RVT-101 success is compromised by Pfizer's news. He reiterates an Overweight rating on Axovant with a $23 price target. The stock Is down 27%, or $4.51, to $12.14 in late morning trading.
10:59 EDTPFEPfizer CEO confident Allergan deal can close in second half
Subscribe for More Information
09:46 EDTPFEIntercept rumored to draw interest from many suitors, Daily Mail says
Subscribe for More Information
08:49 EDTPFEAxovant tumbles after Pfizer halts Alzheimer's study
Shares of clinical-stage drug company Axovant Sciences (AXON) are tumbling in pre-market trading after it came to light that a larger competitor halted its own study of a potential Alzheimer's disease treatment since the drug did not appear to have its intended effect in a clinical study. WHAT'S NEW: According to a post to the U.S. National Institutes of Health's ClinicalTrials.gov, Pfizer terminated its Phase 2 study evaluating the safety and efficacy of PF-05212377 in subjects with Alzheimer's disease with existing neuropsychiatric symptoms on donepezil. "The study was terminated October 23, 2015 as pre-specified, interim analysis futility criteria were met. The termination was not due to safety concerns," the site, which was last updated on January 29, stated. WHAT'S NOTABLE: Axovant's own experimental Alzheimer's therapy, RVT-101, is an orally administered, potent antagonist of the 5-hydroxytryptamine 6 serotonin receptors in the brain, which is a similar mechanism of action to Pfizer's drug candidate. RVT-101 is currently in Phase 3 trials. PRICE ACTION: In pre-market trading, Axovant shares fell $2.68, or 16%, to about $14 per share.
08:36 EDTPFEPiper Jaffray biopharma analyst holds an analyst/industry conference call
Subscribe for More Information
07:42 EDTPFEPressure mounts on big pharma names to shrink, sharpen focus, FT says
Subscribe for More Information
06:54 EDTPFEPfizer expects combination with Allergan to occur in 2H16
Subscribe for More Information
06:52 EDTPFEPfizer sees FY16 adjusted EPS $2.20-$2.30, consensus $2.36
Sees FY16 revenue $49B-$51B, consensus $52.49B. Expects impact of January 2016 FX rates compared to 2015 FX rates to negatively impact adjusted EPS by 9c and revenue by $1.5B. Expects currency impact related to Venezuela to negatively impact EPS by 7c and revenue by $800M. Sees FY16 effective tax rate of approximately 24%. Sees FY16 adjusted R&D expenses $7.3B-$7.8B and adjusted SI&A expenses of $13.2B-$14.2B.
06:49 EDTPFEPfizer reports Q4 Innovative Products revenue $7.64B
Subscribe for More Information
06:47 EDTPFEPfizer reports Q4 adjusted EPS 53c, consensus 52c
Reports Q4 revenue $14.05B, consensus $13.56B.
February 1, 2016
16:01 EDTPFEOptions Update; February 1, 2016
Subscribe for More Information
14:32 EDTPFENotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's open, with earnings consensus, include Exxon Mobil (XOM), consensus 64c... Pfizer (PFE), consensus 52c... United Parcel Service (UPS), consensus $1.42... Dow Chemical (DOW), consensus 70c... Emerson Electric (EMR), consensus 51c... Archer-Daniels-Midland (ADM), consensus 66c... Baxter (BAX), consensus 32c... Sirius XM (SIRI), consensus 3c... Royal Caribbean Cruises (RCL), consensus 92c... Ally Financial (ALLY), consensus 51c... Michael Kors (KORS), consensus $1.46... ADT Corp. (ADT), consensus 46c.
13:25 EDTPFEEarnings Watch: Pfizer shares down approximately 12% since last earnings report
Pfizer (PFE) is scheduled to report fourth quarter earnings before the market open on Tuesday, February 2, with a conference call scheduled for 10:00 am ET. Pfizer, a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. Its product portfolio includes medicines and vaccines, as well as various consumer healthcare products. EXPECTATIONS: Analysts are looking for earnings per share of 52c on revenue of $13.57B, according to First Call. The consensus range for EPS is 49c-54c on revenue of $13.08B-$13.99B. LAST QUARTER: After completing its Hospira acquisition in early September, Pfizer reported third quarter EPS of 60c, which beat consensus estimates of 51c, on revenue of $12.1B, which was also higher than consensus estimates of $11.56B. In Q3 Operational revenue growth in in developed markets was driven primarily by the performance of several key products, including Prevnar 13 in adults, Ibrance and Eliquis -- all products that are early in their life cycles as well as from Lyrica primarily in the U.S., and the inclusion of one month of legacy Hospira U.S. operations. In emerging markets, revenues increased 5% operationally, reflecting continued strong operational growth, primarily from the Innovative Products business. Operational revenue growth was partially offset primarily by the loss of exclusivity and associated generic competition for Celebrex in the U.S., Zyvox in the U.S. and Lyrica in certain developed Europe markets. With its Q3 earnings announcement the company raised its fiscal year 2015 earnings per share view to $2.16-$2.20 from $2.04-$2.10 against a raised revenue view of $47.5B-$48.5B from $46.5B-$47.5B. Commenting on the improved yearly view, the company CFO said "We raised our 2015 financial guidance for reported revenues and adjusted diluted EPS to reflect the strong performance to date of Pfizer-standalone, excluding legacy Hospira operations coupled with an improved business outlook for Pfizer-standalone for the remainder of the year.PFIZER-ALLERGAN DEAL. On November 23, Pfizer and Allergan (AGN) announced that their boards of directors have unanimously approved, and the companies have entered into, a definitive merger agreement under which Pfizer will combine with Allergan. Pfizer at the time said it anticipates the Allergan transaction will deliver more than $2B in operational synergies over the first three years after closing. Pfizer anticipates that the combined company will have a pro forma Adjusted Effective Tax Rate of approximately 17%-18% by the first full year after the closing of the transaction. The transaction is expected to be neutral to Pfizer's Adjusted Diluted EPS in 2017, modestly accretive beginning in calendar year 2018, more than 10% accretive in 2019 with high-teens percentage accretion in 2020. STREET RESEARCH: On December 1, Barclays analyst Geoff Meacham kept an Equal Weight rating on Pfizer after assuming coverage of the name. The analyst maintained a $34 price target for shares.On November 25, SunTrust upgraded Pfizer to Neutral and increased its price target to $37 from $34 on shares. Analyst John Boris said the Allergan deal makes strategic sense, providing much needed growth from earlier life cycle assets with limited therapeutic overlap. PRICE ACTION: Shares of Pfizer are lower by approximately 12% since its last earnings report on October 27. Pfizer shares are trading over 1% lower to $29.97 in afternoon trading ahead of Tuesday morning's earnings.
10:49 EDTPFEPfizer technical comments before earnings
On the downside, an important support level to watch is at the $28 area. This level has been an important support since early 2013. If the news is a negative surprise, the $28 zone is likely to be tested from current levels. A breakdown below $28 would resolve the range bearishly. Next downside objectives may be at the following support levels: $27.30, $26.42. If the news is a bullish surprise, resistance levels to watch as potential upside objectives would be at $30.95, $31.78, and $32.91. A move above $32.50 would end the current longer-term downtrend.
08:09 EDTPFEOptions expected to be active
Options expected to be active: GOOGL GOOG YHOO UPS KORS UPS BAX RCL CCL PFE AET D STR DWA CMG ABT SYK.
06:58 EDTPFEPortola Pharma licensed right to andexanet alfa to Bristol-Myers and Pfizer
Subscribe for More Information
06:57 EDTPFEBristol-Myers and Pfizer sign collaboration with Portola Pharmaceuticals
Subscribe for More Information
January 29, 2016
14:44 EDTPFEPfizer volatility elevated into Q4 and outlook
Subscribe for More Information
05:39 EDTPFEPfizer: LIS awards infliximab biosimilar tender to Inflectra, Reuters reports
Pfizer says that the Norwegian Drug Procurement Cooperation has awarded its product Inflectra an infliximab biosimilar tender, Reuters reports. Reference Link
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use